PMID- 27981043
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 15
DP  - 2016
TI  - Adding to the spectrum of insulin sensitive populations for mixed meal tolerance 
      test glucose reliability assessment.
PG  - 57
LID - 57
AB  - As a measure of insulin sensitivity, the mixed meal tolerance test (MMTT) is a 
      simple technique that can provide robust results. The assay consists of examining 
      plasma glucose, insulin and C-peptide prior to and following the consumption of a 
      test meal. While this procedure has been used in clinical research for several 
      years, there is no set standard protocol, and only until recently has the 
      reliability of this assay been thoroughly evaluated in prediabetes and type 2 
      diabetes subjects. Interestingly, the results from this recent study demonstrated 
      stronger MMTT reliability for the prediabetes and diabetes cohorts compared to 
      obese controls. This finding suggests that the obese control group may have more 
      inherent variability in glucose response during a meal challenge likely due to 
      compensatory influences typically observed in non-diabetic insulin-resistant 
      subjects. Furthermore, this study raises the question whether the MMTT assay is 
      reliable in a non-obese cohort. Therefore, to promote the standardization of this 
      technique and contribute to the band of insulin sensitive populations, we 
      employed the same methodology and test meal as the reference study to evaluate 
      the MMTT reliability in healthy and overweight men. Indeed, the interclass 
      coefficient revealed high glucose response repeatability during the MMTT in 
      insulin-sensitive men. Overall, the MMTT is a reliable test across a range of 
      insulin sensitivity including healthy men. However, we propose further 
      investigation may be required to fully define the utility of this methodology in 
      obese non-diabetic insulin-resistant populations.
FAU - Paglialunga, Sabina
AU  - Paglialunga S
AD  - Celerion, 2420 W Baseline Road, Tempe, AZ 85283 USA.
FAU - Guerrero, Angelica
AU  - Guerrero A
AD  - Celerion, 2420 W Baseline Road, Tempe, AZ 85283 USA ; Current Address: Clinical 
      Trials of Texas, San Antonio, TX USA.
FAU - Roessig, Julie M
AU  - Roessig JM
AD  - XOMA Corporation, Berkeley, CA USA.
FAU - Rubin, Paul
AU  - Rubin P
AD  - XOMA Corporation, Berkeley, CA USA.
FAU - Dehn, Clayton A
AU  - Dehn CA
AD  - Celerion, 2420 W Baseline Road, Tempe, AZ 85283 USA ; Current Address: Umbrella 
      Corporation, San Antonio, TX USA.
LA  - eng
PT  - Editorial
DEP - 20161207
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC5142406
OTO - NOTNLM
OT  - MMTT
OT  - Postprandial glucose
OT  - Reliability
EDAT- 2016/12/17 06:00
MHDA- 2016/12/17 06:01
PMCR- 2016/12/07
CRDT- 2016/12/17 06:00
PHST- 2016/10/01 00:00 [received]
PHST- 2016/11/29 00:00 [accepted]
PHST- 2016/12/17 06:00 [entrez]
PHST- 2016/12/17 06:00 [pubmed]
PHST- 2016/12/17 06:01 [medline]
PHST- 2016/12/07 00:00 [pmc-release]
AID - 279 [pii]
AID - 10.1186/s40200-016-0279-x [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2016 Dec 7;15:57. doi: 10.1186/s40200-016-0279-x. 
      eCollection 2016.